Halozyme's Blueprint: How to Thrive Amid Medicare Price Controls

SAN DIEGO, CA – June 15, 2026

In a sector defined by regulatory headwinds and pricing pressures, Halozyme Therapeutics has just made a remarkably bold claim. The San Diego-based biopharma company announced today it projects “zero to minimal impact” to its royalty revenue from the government’s expanding Medicare Drug Price Negotiation Program through at least 2035. While its peers and partners are reporting hits to their bottom line from the Inflation Reduction Act’s (IRA) pricing provisions, Halozyme appears to have found a way to navigate the storm unscathed.

This confidence stems from the company's analysis of a newly released draft rule from the Centers for Medicare & Medicaid Services (CMS) for the 2029 price negotiation cycle. “There is also no projected impact on the Company’s ability to execute new ENHANZE® partnership agreements where improving the patient treatment experience and competitive differentiation continue to be the top reasons ENHANZE is utilized,” said CEO Dr. Helen Torley in a statement. The announcement positions Halozyme not just as a survivor of the industry’s biggest shift in decades, but as the potential architect of a new blueprint for resilience. The central question is whether this is a masterclass in strategic positioning or a temporary haven in a regulatory cat-and-mouse game.

A Business Model Built for Resilience

Halozyme’s perceived immunity isn't an accident; it’s a function of a business model that is fundamentally different from that of a traditional drugmaker. The company doesn't sell blockbuster drugs. Instead, it licenses its proprietary ENHANZE® drug delivery technology to the companies that do. ENHANZE uses an enzyme to temporarily break down a natural barrier under the skin, allowing large-volume biologic drugs that would typically require lengthy intravenous (IV) infusions in a clinic to be delivered via a simple subcutaneous injection, often in minutes at home.

This “picks and shovels” strategy means Halozyme collects royalties from partners like Roche, Janssen, and Pfizer, rather than selling the high-priced drug itself. The IRA’s price negotiation program targets the manufacturer of the “single source drug,” not the technology licensor. Furthermore, Halozyme’s outlook is bolstered by key provisions in the legislative framework. The “One Big Beautiful Bill Act” of 2025 significantly expanded protections for orphan drugs, many of which use ENHANZE®. This shields a swath of partnered products from negotiation. The company also points to rules regarding the entry of biosimilars, which can remove a drug from the negotiation list, as another layer of protection for its royalty streams.

The Fine Print in Washington's War on Drug Costs

Halozyme’s confidence is particularly striking because it comes just as CMS is attempting to close what it sees as a major loophole. The new draft rule for 2029 explicitly targets “program integrity concerns posed by certain new formulations”—a direct shot at the practice critics call “product hopping” or “evergreening.” This is where a company launches a new version of a drug, such as a subcutaneous formulation of an older IV drug, just as the original is about to lose patent protection and face price negotiations.

Since facilitating this exact IV-to-subcutaneous switch is Halozyme’s core business, the company would appear to be directly in the crosshairs. However, its leadership and many analysts believe the specifics of the rule still work in its favor. The rule suggests that Medicare could exempt a newer subcutaneous formulation from price ceilings if biosimilars of the older IV version enter the market and create price competition. For Halozyme and its partners, this is a feature, not a bug. It suggests a pathway where the value of patient convenience is recognized, and the new formulation is treated as a distinct, innovative product, insulating it from the price controls applied to its predecessor. “The government seems to be making a distinction between a simple patent extension and a new formulation that genuinely reduces the burden on the healthcare system,” one healthcare policy expert noted.

The Ripple Effect on Innovation and Partnerships

This regulatory clarity, if it holds, could make Halozyme an even more attractive partner. For a pharmaceutical giant facing a patent cliff and the looming threat of IRA price negotiations on a key IV biologic, partnering with Halozyme to develop a subcutaneous version now looks like a strategically sound de-risking maneuver. The continued deal flow, including recent collaborations with GSK and Oruka Therapeutics announced in the past quarter, suggests the industry is already voting with its feet.

The dynamic creates a fascinating tension. On one hand, as some analyses like a recent L.E.K. Consulting report suggest, the IRA’s shorter product lifecycles could discourage investment in next-generation formulations. On the other, Halozyme's situation suggests the opposite: the threat of price controls may actually accelerate the adoption of value-adding technologies like ENHANZE® as a defensive strategy. This is a win for patients who gain access to more convenient treatments and for a healthcare system that can potentially reduce costs associated with hospital-based infusions.

Wall Street's Wager and Lingering Questions

Financial markets have largely rewarded Halozyme’s position. Analysts at firms like Citizens and Benchmark have reiterated buy ratings, citing clarity on long-term revenue drivers and a business model that is proving its durability. The company’s strong first-quarter 2026 performance, which handily beat expectations, provides a solid foundation for its optimistic forward guidance.

Yet, caution persists. Goldman Sachs, while raising its price target, maintains a Neutral rating, pointing to the broader IRA impact on Halozyme’s partners and long-term challenges like the eventual ENHANZE patent cliff and emerging competition. The success of Halozyme's partners is not guaranteed, as evidenced by Q1 reports from Amgen and AbbVie, who both cited IRA negotiations as a drag on sales for their respective drugs. Halozyme's fate remains tethered to the success of the products that use its technology. The company is actively working to mitigate this by expanding its portfolio, as seen in its recent acquisition of Elektrofi and development of its Hypercon™ platform, but the core of its value proposition remains ENHANZE®. The coming years will reveal whether Halozyme has truly created a durable blueprint for navigating the new world of pharmaceutical pricing, or if it has simply found a clever, but ultimately temporary, path around it.